Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.46 |
| ▸ | FABP7 | O15540 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 3/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29989813 | 1.00 | KMT2A (0.55) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL28975484 | 0.92 | KMT2A (0.48) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL6136463 | 0.92 | KMT2A (0.56) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL29670230 | 0.92 | KMT2A (0.56) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL13329984 | 0.91 | KMT2A (0.58) | KMT2AFABP5FABP7CASP3EPHX2 | |
| Succinic Acid SCHEMBL27739367 | 0.90 | KMT2A (0.48) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL5148054 | 0.90 | KMT2A (0.60) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL5031690 | 0.88 | KMT2A (0.53) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL31300437 | 0.88 | KMT2A (0.46) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL12261072 | 0.86 | KMT2A (0.57) | KMT2AFABP5FABP7CASP3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125481-A1 | ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. | 2026-05-07 | — | — | US | disclosed |
| US-12545735-B2 | Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4631955-A1 | PURIFICATION METHOD AND PRODUCTION METHOD OF CYCLIC PEPTIDE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-15 | — | — | EP | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| EP-4603105-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT AGAINST HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-20 | — | — | EP | disclosed |
| US-20250250342-A2 | ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. | 2025-08-07 | — | — | US | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-07-17 | — | — | US | disclosed |
| EP-4512818-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2025-02-26 | — | — | EP | disclosed |
| US-20250051394-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-02-13 | — | — | US | disclosed |
| US-20010007016-A1 | PEPTIDE DERIVATIVES | SAKURADA SHINOBU (JP) | 2001-07-05 | — | — | US | disclosed |
| US-6228841-B1 | N-METHYLTYROSINE-ARGININE-PHENYLALANINE-N-METHYL-B-ALANINE OR ITS SALT; ANALGESIC FOR CANCER PAIN | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-05-08 | — | — | US | disclosed |
| US-6051685-A | MODIFIED TRIPEPTIDE OF TYROSINE-D-ARGININE-PHENYLALANINE OR SALT WITH AMIDINO GROUP AT N-TERMINAL; ANALGESIC WHICH ACTS THROUGH ACTIONS OF OPIOID RECEPTORS; WITH SIDE EFFECT REDUCTION FOR USE IN TREATING CANCEROUS PAIN | DAIICHI PHARMACEUTICALS CO., LTD. (JP) | 2000-04-18 | — | — | US | disclosed |
| EP-0755942-B1 | N-AMIDINO DERMORPHIN DERIVATIVE | DAIICHI SEIYAKU CO (JP) | 1999-08-04 | — | — | EP | disclosed |
| CN-1202174-A | Peptide derivatives | DAIICHI SEIYAKU CO (JP) | 1998-12-16 | — | — | CN | disclosed |
| CN-1200736-A | Peptide derivatives | DAIICHI SEIYAKU CO (JP) | 1998-12-02 | — | — | CN | disclosed |
| EP-0861849-A1 | PEPTIDE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1998-09-02 | — | — | EP | disclosed |
| EP-0850950-A1 | PEPTIDE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1998-07-01 | — | — | EP | disclosed |
| CN-1148392-A | Peptide derivative | DAIICHI SEIYAKU CO (JP) | 1997-04-23 | — | — | CN | disclosed |
| EP-0755942-A1 | PEPTIDE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010007016-A1 | PEPTIDE DERIVATIVES | NPR1, NPR3, NGLY1 | KMT2A 2181/4885FABP5 2884/4885FABP7 485/4885 |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | KMT2A 1250/4885FABP5 4631/4885FABP7 4721/4885 |
| US-20250250342-A2 | ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF | MET, HGF, HGFAC | KMT2A 1102/4885FABP5 1802/4885FABP7 1021/4885 |
| US-20250051394-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | KMT2A 1250/4885FABP5 4631/4885FABP7 4721/4885 |
| US-12545735-B2 | Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof | MET, HGF, FCGR2A | KMT2A 769/4885FABP5 2002/4885FABP7 1753/4885 |
| US-20260125481-A1 | ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF | MET, HGF, HAVCR2 | KMT2A 514/4885FABP5 2192/4885FABP7 1649/4885 |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | KMT2A 1250/4885FABP5 4631/4885FABP7 4721/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | KMT2A 3145/4885FABP5 4094/4885FABP7 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.